Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer

What happened: Reed Jobs, founder of oncology venture firm Yosemite and son of Steve Jobs, said GLP-1 drugs could significantly impact cancer and cardiovascular disease, calling them some of the most important medicines to reach the market. Key numbers: A JAMA Oncology study of 86,632 adults found GLP-1 Why it matters: Jobs compared obesity to smoking as a risk factor and said the drugs could help make cancer manageable, while noting drawbacks such as muscle loss. Eli Lilly said retatrutide delivered more than double the weight loss of the highest approved Ozempic dose in a Phase 3 trial. Market: +1.5% today ($348.91), +29.0% YTD, 1.0x vol — as of 23:45 UTC

Reed Jobs, founder of oncology venture firm Yosemite and son of Steve Jobs, said GLP-1 drugs could significantly impact cancer and cardiovascular disease, calling them some of the most important medicines to reach the market.

Jobs compared obesity to smoking as a risk factor and said the drugs could help make cancer manageable, while noting drawbacks such as muscle loss. Eli Lilly said retatrutide delivered more than double the weight loss of the highest approved Ozempic dose in a Phase 3 trial. Market: +1.5% today ($348.91), +29.0% YTD, 1.0x vol — as of 23:45 UTC